CAPRISA, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
J Infect Dis. 2021 Feb 13;223(3):370-380. doi: 10.1093/infdis/jiaa377.
Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally. Early studies on bnAbs showed safety in humans, but short elimination half-lives and low potency and breadth. Since 2010, several new highly potent bnAbs have been assessed in clinical trials alone or in combination for HIV prevention. Published data indicate that these bnAbs are safe and have a half-life ranging from 15 to 71 days. Only intravenous VRC01 has advanced to an efficacy trial, with results expected in late 2020. If bnAbs are shown to be effective in preventing HIV infection, they could fast-track vaccine development as correlates of protection, and contribute as passive immunization to achieving the goal of epidemic control. The purpose of the current review is to describe the current status and provide a synopsis of the available data on bnAbs in clinical trials for HIV prevention.
被动免疫接种广泛中和抗体（bnAbs）是减少全球每年 170 万例人类免疫缺陷病毒（HIV）感染的一种很有前途的方法。早期对 bnAbs 的研究表明其在人体中是安全的，但消除半衰期短、效力和广度低。自 2010 年以来，已有数种新的高效 bnAbs 在临床试验中单独或联合用于 HIV 预防进行了评估。已发表的数据表明，这些 bnAbs 是安全的，半衰期在 15 至 71 天之间。只有静脉注射 VRC01 已进入疗效试验，预计 2020 年底将得出结果。如果 bnAbs 被证明能有效预防 HIV 感染，它们可能会作为保护相关因素快速推进疫苗开发，并作为被动免疫为实现控制疫情的目标做出贡献。本综述的目的是描述当前的状况，并提供有关 bnAbs 在 HIV 预防临床试验中数据的概述。
